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Safety and Efﬁcacy of Carotid Stenting in the Treatment of Carotid Artery
Stenosis: Immediate Results and Long Term Follow-up
Cinzia Moncalvo1, Vincenzo Puma1, Giuseppe Celano1, Mario Caprile1,
Angelo Laurenza1, Giuseppe Carosio1, Paolo Ciofﬁ1
1Clinica Città di Alessandria, Alessandria, Italy
Background: Carotid artery stenting may be an alternative to surgical endoarter-
ectomy for the treatment of atherosclerotic carotid artery stenosis. Aim of our study: to
analyze retrospectively the procedures of Carotid artery stenting performed in our
Centre between January 2004 and December 2012.
Methods: This analysis includes 604 procedures performed in 554 patients (382 men;
mean age: 72 years old). Symptomatic patients with carotid artery stenosis> 50% were
the 45%; we treated asymptomatic patients affected by > 70% stenosis. 398 patients
(72%) were considered at high surgical risk: 207 (37%) with severe controlateral
stenosis; 136 (24%) with severe or unstable angina, poor left ventricular function,
left main desease or trivascular coronary artery disease, severe cardiac valve disease;
35 patients (6%) presented restenosis after surgical treatment. 28 (5%) patients were
treated with urgent coronary artery by-pass grafting (CABG) immediately after Carotid
artery stenting; 108 (19%) patients underwent staged CABG one month after Carotid
artery stenting. Distal cerebral protection devices were used in 85% of the procedures.
Soft plaques were present in 110 patients (18%). 49 (9%) patients were submitted to
Carotid artery stenting for bilateral carotid artery stenosis.
Results: Successful immediate angiographyc result in 99% of the patients. Major com-
plications occurred in 11 patient (1.9%) and included: death (1 fatal stroke), major stroke
(3), intracerebral hemorrhagic stroke (1), minor stroke (5), acute instent thrombosis (1
patient treated with thromboendoarterectomy and stent removal). Puncture site hematoma
occurred in4patients treatedwithvascular surgical repair, onepatient died for hemorrhagic
shock. Complete follow up in 95% of the patients. Instent restenosis occurred in 6 patients
(1%) and was successfully treated with a new stenting. 50 patients died (22 for car-
diovascular causes), but no one died for causes directly related to Carotid artery stenting.
Conclusions: In our experience Carotid artery stenting is a safety procedure with low
complications also in high risk patients; the long term efﬁcacy of Carotid artery
stenting is very good with low rate of restenosis.
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Internal Carotid Artery “Near-occlusion”: Multi-detector CT Angiography
Assessment At Baseline And After Carotid Artery Stenting
piero montorsi1, andrea annoni2, stefano Galli3
1University of Milan, Milan, Italy, 2department of clinical sciences, milan, Italy,
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Background: Carotid “near-occlusion” (NO) is a high-grade stenosis of the internal
carotid artery (ICA) with collapse of the distal lumen. No data have been reported
regarding ICA ﬂow and lumen diameter recovery after surgical or endovascular treatment.
Methods: Twenty-nine consecutive patients (male 73%, mean age 709 years) with
NO were submitted to ICA stenting with cerebral protection. Multi-detector CT
angiography (MDCTA) was carried out at baseline and at follow-up after CAS in all
patients.Diameter of distal target and contralateral ICA were measured at 3 cm interval
from carotid bifurcation on both sides. Carotid stenosis was calculated with the ECST
method. NO was deﬁned as target ICA/contralateral ICA distal diameter ratio 0.87
by MDCTA and distal diameter of target ICA 3.6 mm.
Results: ICA stenosis was 942.9% by MDCTA.One patient was excluded because of
tandem intracranial stenosis. CAS was technically and cinically successful in 26/28
(93%) patients. At 27196 day-F/U, neither MACCE nor US Doppler ISR occurred.
The target ICA distal diameter was 3.00.4 mm and the target ICA/contralateral ICA
distal diameter ratio was 0.640.10. The ratio raised to 0.970.12(p< 0.0001) as a
result of target ICA distal diameter increase from 3.00.4 mm to 4.00.48 mm (p<
0.0001) and contralateral ICA distal diameter decrease from 4.70.51 mm to 4.10.43
mm(p< 0.0001). A correlation was found between baseline measures and delta changes
after CAS: the smaller the baseline diameter of the target vessel, the greater the increase
at follow-up and vice versa for contralateral ICA (R¼-0.42, p¼0.033 for target ICA
diameter and R¼-0.62, p¼0.0007 for contracontralateral ICA diameter). No signiﬁcant
changes occurred in either common or external carotid artery on both sides.
Conclusions: MDCTA is a safe and effective technique to assess the effects of
endovascular revascularization. After CAS, target ICA distal diameter increases
associated with a decrease of contralateral ICA distal diameter likely due to the
disappearance of a of a compensatory phenomenon.
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Background: Carotid artery stenting (CAS) has become an alternative to carotid
endarterectomy (CEA) in selected patients. Therefore, we aimed to evaluate resultsB164 JACC Vol 64/11/Suppl B j September 13–17, 2of the optimal revascularization strategy with CAS and CEA, in accordance
with our algorithm based on cardiovascular team decision in the all-comers
registry.
Methods: In this prospective registry, 296 consecutive patients who underwent 333
carotid artery revascularization procedures were enrolled. Asymptomatic patients with
at least 70% stenosis as well as symptomatic with at least 50% stenosis were enrolled.
The method was selected by interventional cardiologist and vascular surgeon, based
upon plaque morphology and cardiovascular risk.
Results: Stenting was performed in 199 cases, while CEA in 134. There were no
signiﬁcant differences with regard to basic demographic and clinical characteristics
between CAS and CEA groups except higher occurrence of coronary artery disease
(88,4% vs. 65,7%, p< 0,01), diabetes (37,7% vs. 20,9%, p< 0,01) and prior MI (32,5%
vs 20,3%, p< 0,02) in CAS. There were no differences between cardio and cerebro-
vascular events at discharge. At long-term (median 660 days) there were no signiﬁcant
differences between CAS and CEA with regard to mortality (8,3 vs. 10,6%, p¼0,56) and
stroke incidence (7,5 vs. 7,4% , p¼0,98). The risk of myocardial infarction was
signiﬁcantly lower in the CAS when compared to CEA (0 vs. 4,2%, p¼0,01).
Conclusions: Basing upon cardiovascular team decision, at long term, CAS appears to
be equivalent to CEA to stroke and mortality risk, however the odds of myocardial
infarction were lower after CAS.
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Carotid Artery Stenting In Patients With Contra-lateral Stenosis Or Occlusion.
A Single Center Experience Of More Than 1100 Cases
Jürgen Kammler1, Alexander Kypta1, Klaus Kerschner1, Michael Grund1,
Thomas Lambert1, Karim Saleh1, Simon Hönig1, Hermann Blessberger1,
Clemens Steinwender1
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Background: Carotid artery stenting (CAS) is assumed to be associated with a higher
complication rate in patients (pts) with a contra-lateral occlusion or stenosis of more
than 50%. We retrospectively analyzed data from our center to quantify complication
rates in patients undergoing CAS in these subgroups.
Methods: In a series of 1125 consecutive pts undergoing CAS in our center between
December 1997 and January 2014, 87 pts (7.7%) had a contra-lateral occlusion of the
carotid artery (group 1), and 215 pts (19.1%) had a contra-lateral stenosis of > 50%
(group 2), and 823 pts (73.2%) had no contra-lateral stenosis (group 3).
Results: CAS was successful in all patients but 30 (28 of them in group 3, and two in
the group 2). Stenting was successful in all cases of pts of group 1. The mean degree
of stenosis was reduced from 82.7  9.7% to 3.2  7.5% in group 1, 86.3  8.6% to
3.8  8.2% in group 2 and 85.8  10.4% to 3.2  6.5% in group 3, respectively. The
mean stent length was 24.1  8.9 mm in group 1, 26.9  9.6 mm in group 2 and 27.7
 10.0 mm in group 3. The mean intervention time was 16.8  11.0 min, 16.3  11.3
min and 16.9  10.6 min in these three groups. The rate of major cerebral compli-
cations (fatal or non-fatal major stroke, minor stroke, PRIND, TIA) was 8.1% in group
1, 9.8% in group 2 and 8.5% in group 3 (p¼ns between all groups). As cerebral
protection devices were consecutively used since April 2004, 37 pts of group 1
(42.5%), 124 pts of group 2 (57.7%) and 499 pts in group 3 (60.9%) were stented
under cerebral protection, respectively. The use of protection devices was associated
with a signiﬁcant reduction of the complication rate in all 3 groups (5.4% in group 1,
6.5% in group 2 and 6.8% in group 3, respectively) with no signiﬁcant difference
between all groups.
Conclusions: Compared to pts. with a patent contra-lateral vessel, CAS in pts with
contra-lateral stenosis or occlusion is not associated with an increased risk for peri-
interventional cerebral complications. The use of cerebral protection devices for CAS
reduces peri-interventional cerebral complication rates in patients with and without a
patent contra-lateral vessel.
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Outside the Indications in Patients With Thoracoabdominal Pathologies
Niamh Hynes1, Mohammed Sultan1, Sherif Sultan2
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Background: To scrutinize registry data on thoracoabdominal repairs performed
using the Multilayer Flow Modulator (MFM) outside the indications for use (IFU) and
analyze the adverse outcomes.014 j TCT Abstracts/Aortic Endograft Intervention (not aortic stenosis)
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: Of 380 patients from Europe registered in the MFM Global Registry after
treatment for thoracoabdominal aortic aneurysm (TAAA) or dissection, 38 (10%)
patients (30 men; median age 71 years, range 30–91) treated a compassionate basis
outside the IFU were analyzed. Thirteen patients had chronic Stanford type B
dissection with aneurysmal dilatation >6 cm. There were 6 mycotic and 4 saccular
aneurysms in addition to 15 primary TAAAs. The mean aneurysm diameter was 7.1
cm. Ten patients presented with rupture, and 23 patients had previous open or thoracic
endovascular aortic repair (TEVAR).
Results: Although no death, paraplegia, stroke, or renovisceral compromise was docu-
mented during the initial hospital stay, technical success was zero. There were 31 cases
(81.6%) inwhich therewas failure to land thedevice innormal aorta.Other violations of the
IFU included 12with inadequate stent overlap and 11 cases involving a smallMFMbeing
deployed inside a larger one. Overall survival, freedom from aneurysm-related death, and
rupture-free survival estimates were 17.5%, 25.0%, 31.5%, respectively, at 18 months.
There were 8 visceral branch complications; in all, 14 secondary endovascular in-
terventions were required in 11 patients for endoleak or stent foreshortening. No false
lumen was completely thrombosed in the dissecting aneurysms. All aneurysms showed a
mean sac growth rate of 0.120.16 cm/month. Factors having a signiﬁcance inﬂuence on
risk of aneurysm-related death included aneurysm diameter (p¼0.025), previous TEVAR
(p¼0.03), and inadequate overlap between devices (p< 0.002).
Conclusions: There are clinical scenarios in which the MFM does not perform well.
MFM is not a solution for patients living on borrowed time and should not be used
indiscriminately in patients in whom other modalities of aortic repair are not feasible.
It use must adhere to the IFU, and robust clinical data are required before constructing
a randomized controlled trial.
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Impact of Type-II Endoleak on Aneurysm Sac Growth and Predictors of Type-II
Endoleak after Endovascular Aneurysm Repair
Ren Kawaguchi1, Yusuke Miyaishi1, Hakuken Kan1, Masahiko Ezure1,
Tatsuo Kaneko1, Shigeru Oshima1
1Gunma Prefectural Cardiovascular Center, Maebashi, Japan
Background: Type-II endoleak(T-II) after endovascular abdominal aneurysm
repair(EVAR) is an unresolved phenomenon. We aimed to investigate the impact of
T-II on aneurysm sac growth and reveal preoperative T-II predictors.
Methods:Weenrolled162consecutivepatients(Zenith:61,EXCLUDER:57,ENDURANT:44)
who underwent successful EVAR without Type-I or Type-III endoleak and had at least
1-year follow-up. Computed tomography(CT) before and after EVAR(1week, 6month, and
1year) were reviewed to estimate T-II and measure sac diameter. Three-dimensional vol-
ume analyses were performed during CT for measuring sac volume. Vessel number and
diameter of the patent lumbar artery(LA) and inferior mesenteric artery(IMA) were eval-
uated. Variable anatomical parameters and patient characteristics were investigated as
possible T-II predictors.
Results: T-II was 35.8%, 15.4%, and 12.3% at 1week, 6months, and 1year after EVAR,
respectively. The mean preoperative maximum sac diameter and volume were
50.18.2mm and 153.875.5ml, respectively, without differences between T-II
cases(T-II-group) and absence of T-II cases(non-T-II-groups). Signiﬁcant differences in
the reduction of sac diameter(T-II-group:-0.113.4mmvs non-T-II-group:-7.36.0mm
p< 0.0001) and volume(T-II-group:-0.0714.6ml vs non-T-II-group:-24.230.7ml
p¼0.0007) was observed between two groups at the 1year after EVAR. Sac growth
was observed in 47.6% cases in the T-II-group. EXCLUDER use, patent LA, patent
IMA, and IMA diameter were signiﬁcantly associated to T-II- at 1week after EVAR
in univariate analysis. Dual antiplatelet therapy(DAPT), EXCLUDER use, number of
LA and patent IMA were signiﬁcantly associated to T-II at 1year after EVAR. Multi-
variate analysis revealed that DAPT and EXCLUDER use were independent predictors
of T-II at 1year after EVAR. Patent IMA was the only signiﬁcant correlative factor of
sac growth in patients with persistent T-II.
Conclusions: Persistent T-II after EVAR was observed in 12% cases. DAPT and
EXCLUDER use were independent predictors of persistent T-II. Sac growth was
observed in half of the patients with persistent T-II. Because T-II with patent IMA was
signiﬁcantly associated with sac growth, careful observation or additiona.
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Intravascular Ultrasound Guidance for Percutaneous Treatment of Aortic
Coarctation
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Background: Percutaneous treatment of aortic coarctation (AC) is usually guided
with intravascular contrast injections and hemodynamic parameters. Intravascular
ultrasound (IVUS) guidance might be useful to choose adequate balloons and stents
sizes and to optimize the ﬁnal result after angioplasty, but there are few reports in the
literature.
Methods: Eleven patients (91% male), mean age 2418 years (range 7-63), with a
diagnosis of native AC (36%) or recoarctation (64%) conﬁrmed with non-invasive
imaging techniques (echocardiography and magnetic resonance or computerized to-
mography), were included. Simultaneous radial and femoral access was used in all cases.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AoAfter standard aortography in 2 projections (lateral and anteroposterior), the anatomy of
the aorta was studiedwith IVUS (Ultra ICE 9F 9MHz, Boston Scientiﬁc) from the arch
down to the diaphragm, and again after the angioplasty was performed.
Results: The procedure was successful in all cases. Mean gradient changed from
339 mmHg (baseline) to 45 mmHg (ﬁnal). Minimal lumen diameter of the AC
with angiography was 8.12.2 mm and with IVUS 9.41.9 mm (p< 0.05). Stents
were implanted in 10 patients (91%), in seven cases covered stents were used and bare
metal stents in the rest. One patient was treated only with high pressure inﬂation of a
non-compliant balloon inside a previously implanted stent. Mean diameter of the
balloons where the stent was mounted was 15.62.9 mm (12-22), mean length of the
stent was 35.55.3 mm (28-45), and mean diameter of postdilatation balloons was
174.2 mm (12-25). Intrastent postdilatation was performed in 73% of cases, mainly
due to signiﬁcant stent infraexpansion detected with IVUS. All patients were dis-
charged in 24-48 hours without signiﬁcant complications. The use of IVUS changed
the initial strategy, based only in angiography, in 73% of cases (balloon size, stent
length or need for postdilatation).
Conclusions: IVUS guidance during percutaneous treatment of AC modiﬁes in a high
percentage of cases the treatment strategy based only in angiography. There are sig-
niﬁcant anatomic differences between angiographic and IVUS measures.
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THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF THORACO ABDOMINAL AND ABDOMINAL AORTIC ANEURYSMS.
MOROCCAN EXPERIENCE
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Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by inter-
ventional procedures (endografts, fenestrated, branched grafts, chimney techniques).
We used a new concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
Methods: This selfexpandable M.F.M is a 3 D braided tube made of several inter-
connected layers without any covering. We will explain and demonstrate the key
principles of the stent leading to thrombosis, shrinkage of the A, eliminating the risk of
rupture. Moreover, this M.F.M preserves the collateral branches allowing the possi-
bility to cover any artery without compromising the ﬂow (renal, digestive arteries,
supra aortic vessels.)
Results: 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated with MFM in
very high risk patients. 53 MFM implanted (1 to 5 per pt). o Technical success: 100%
o At 30 days: no neurological complication, branch patency 100%, no death o During
the follow up we had 3 deaths not device related. CT scan control performed at 1, 3, 6,
12, 18 months with calculation of A. Diameters and Volumes. o All collateral
branches remain patent and we observed a progressive thrombosis and shrinkage of
the aneurysmal sac depending on the size of the collaterals. Some patients developped
a thrombus after 1 month, some after 6 months and some even after 18 months. o A
signiﬁcant mean diameter reduction was observed between baseline and 6 months:
17,25 mm reduction for the transversal diameter, 13,83 mm for the antero posterior
diameter in the TAAA group. o Overtime the ratio thrombus volume / Total Volume is
increasing and the ratio Residual Flow Volume / Total Volume is decreasing. The
problems of thrombosis, shrinkage and volume reduction of the aneurysmal sac will
be discussed. The complications rates with M.F.M appear lower in comparison with
current endovascular techniques, and with surgery.
Conclusions: The M.F.M represents an alternative to current devices to treat TAAA
and AAA. It is a safe procedure with a low complication rate. The ﬁrst results are
promising. A larger study is ongoing.
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Aortic Dissection and Mortality During Pregnancy in the United States:
A 10-Year Analysis
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Background: Aortic dissection during pregnancy is a morbid condition for both the
mother and her fetus. There is scant data on the incidence, risk factors, and outcomes
of aortic dissection during pregnancy.
Methods: The Nationwide Inpatient Sample (NIS) Database was queried for cases of
pregnancy and aortic dissection from 1998-2008. The primary analysis identiﬁed
speciﬁc medical co-morbidities increasing the risk of aortic dissection during
pregnancy.
Results: We identiﬁed 10,550,421 pregnant women and 41,088 aortic dissections in the
NIS Database from 1998-2008. From these cases, we identiﬁed 44 cases of aortic
dissection in pregnancy. The rate of aortic dissection in pregnancy was .0004%, and
represented only 0.1% of all cases of aortic dissection. Mean age of aortic dissection was
younger (31-years-old vs. 69-years-old). The incidenceofMarfan’s syndromewashigher
(15.9% vs. 1.8%, p< 0.00001) and the incidence of hypertension was lower (18.2% vs.
68.3%, p< 0.00001). 14 out of the 44 pregnant patients with aortic dissection underwent
operative repair of the aorta. Patient death was lower in cases of aortic dissection during
pregnancy compared to the general population (6.8% vs. 15.4%, p< 0.03).
Conclusions: Aortic dissection during pregnancy is an extremely rare event with a
signiﬁcantly higher incidence of Marfan’s Syndrome but lower incidence of mortality.rtic Endograft Intervention (not aortic stenosis) B165
